(Les stocks de biotechnologies ont atteint un creux de 52 semaines le 20 novembre)
- Fresenius Medical Care AG et Cie (NYSE: FMS )
- Adamas Pharmaceuticals Inc (NASDAQ: ADMS )
- Akebia Therapeutics Inc (NASDAQ: AKBA )
- Aquestive Therapeutics Inc (NASDAQ: AQST )
- Cancer Genetics Inc (NASDAQ: CGIX) ) (a enregistré une baisse de ses revenus et une perte plus importante pour le troisième trimestre)
- Celgene Corporation (NASDAQ: CELG) )
- Cellectis SA (NASDAQ: CLLS )
- Celsion Corporation (NASDAQ: CLSN) )
- CTI BioPharma Corp (NASDAQ: CTIC) )
- Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) )
- CytomX Therapeutics Inc (NASDAQ: CTMX )
- DURECT Corporation (NASDAQ: DRRX )
- Endologix, Inc. (NASDAQ: ELGX )
- Erytech Pharma SA (NASDAQ: ERYP )
- Kala Pharmaceuticals Inc (NASDAQ: KALA )
- Keryx Biopharmaceuticals (NASDAQ: KERX )
- KITOV PHARMA LT / S ADR (NASDAQ: KTOV )
- Kodiak Sciences Inc (NASDAQ: KOD )
- Mersana Therapeutics Inc (NASDAQ: MRSN )
- Mesoblast limité (NASDAQ: MESO )
- Neos Therapeutics Inc (NASDAQ: NEOS )
- Neovasc Inc (NASDAQ: NVCN )
- Novan Inc (NASDAQ: NOVN )
- OptiNose Inc (NASDAQ: OPTN )
- PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS )
- Revance Therapeutics Inc (NASDAQ: RVNC )
- SCYNEXIS Inc (NASDAQ: SCYX )
- Sutro Biopharma Inc (NASDAQ: STRO )
- Teligent Inc (NASDAQ: TLGT )
- Tenax Therapeutics Inc (NASDAQ: TENX )
- Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) )
Aucun commentaire:
Enregistrer un commentaire